Drug Trial Radar · NCT07684586
A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation Prototypes
Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jul 2, 2026
Primary completion
Aug 27, 2027
Study completion Aug 27, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jul 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label study being conducted in healthy adults, to learn what happens to the study medicine (camlipixant) they are receiving in a person's body over time (a pharmacokinetic \[PK\] study). The goal of the study is to understand how the body processes camlipixant, to check its safety and how well it is tolerated. Participants will receive camlipixant at different dose levels with different formulation types either on an empty stomach or after a meal.
Conditions
- Cough
Interventions
CamlipixantDrug
Camlipixant will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Concentration (Cmax) of CamlipixantTime frame: Pre-dose and up to 48 hours post dose
- Area Under the Curve from Zero up to 24 hours [AUC (0-24)] of CamlipixantTime frame: Pre-dose and up to 24 hours post dose
- Observed Concentration of Camlipixant at 24 hours (C24)Time frame: 24 hours post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Nottingham, Nottinghamshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.